BLUEBIRD BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9228 USD | +1.13% |
|
-9.53% | -33.13% |
| Apr. 26 | Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report | MT |
| Mar. 27 | Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,426 | 4,855 | 2,872 | 700.4 | 573.7 | 177.9 | 177.9 | - |
| Enterprise Value (EV) 1 | 4,194 | 3,749 | 1,721 | 400.9 | 393.4 | -62.74 | 71.98 | 114.1 |
| P/E ratio | -9.29 x | -6.13 x | -4.35 x | -0.84 x | -2.04 x | -0.55 x | -0.58 x | -1.12 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 99.4 x | 109 x | 11.5 x | 191 x | 160 x | 4.75 x | 1.42 x | 0.69 x |
| EV / Revenue | 76.8 x | 83.9 x | 6.86 x | 109 x | 109 x | -1.68 x | 0.57 x | 0.44 x |
| EV / EBITDA | -7.56 x | -4.7 x | -2.85 x | -0.7 x | -1.04 x | 0.24 x | -0.32 x | -0.83 x |
| EV / FCF | -8.94 x | -5.9 x | -3.45 x | -0.62 x | - | 0.19 x | -0.22 x | -0.49 x |
| FCF Yield | -11.2% | -16.9% | -29% | -162% | - | 521% | -449% | -206% |
| Price to Book | 2.88 x | 3.78 x | 2.12 x | 1.9 x | 2.92 x | 0.45 x | 1.26 x | 1.47 x |
| Nbr of stocks (in thousands) | 54,694 | 55,331 | 66,373 | 70,107 | 82,910 | 192,742 | 192,742 | - |
| Reference price 2 | 99.20 | 87.75 | 43.27 | 9.990 | 6.920 | 0.9228 | 0.9228 | 0.9228 |
| Announcement Date | 2/21/19 | 2/18/20 | 2/23/21 | 3/4/22 | 3/29/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 54.58 | 44.67 | 250.7 | 3.662 | 3.597 | 37.41 | 125.4 | 257.9 |
| EBITDA 1 | -554.9 | -797.4 | -603.7 | -571.3 | -379.2 | -266.4 | -226.3 | -138.2 |
| EBIT 1 | -572 | -814.8 | -623 | -590.9 | -384.2 | -283 | -259.5 | -177.3 |
| Operating Margin | -1,048.06% | -1,823.94% | -248.49% | -16,136.29% | -10,679.79% | -756.35% | -206.96% | -68.72% |
| Earnings before Tax (EBT) 1 | -555.4 | -790.2 | -618 | -562.4 | -266.5 | -198.8 | -244.6 | -154.5 |
| Net income 1 | -555.6 | -789.6 | -618.7 | -819.4 | -266.6 | -199.1 | -236.3 | -155.2 |
| Net margin | -1,018.02% | -1,767.49% | -246.75% | -22,375.15% | -7,411.12% | -532.17% | -188.44% | -60.16% |
| EPS 2 | -10.68 | -14.31 | -9.950 | -11.89 | -3.390 | -1.664 | -1.597 | -0.8228 |
| Free Cash Flow 1 | -469.2 | -635.4 | -499.3 | -650.1 | - | -327 | -323 | -235 |
| FCF margin | -859.6% | -1,422.33% | -199.15% | -17,753.74% | - | -874.06% | -257.62% | -91.11% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/21/19 | 2/18/20 | 2/23/21 | 3/4/22 | 3/29/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.472 | 22.68 | 1.606 | 1.945 | 1.519 | 0.071 | 0.062 | 2.381 | 6.89 | 12.39 | 13.88 | 19.23 | 21.78 | 31.92 | 51.67 |
| EBITDA 1 | -234.8 | -190.8 | -133.4 | -119.3 | -99.42 | -85.09 | -75.31 | -83.41 | -84.33 | -83.66 | -102.3 | - | - | - | - |
| EBIT 1 | -240.8 | -196.8 | -135.7 | -120.3 | -100.8 | -86.48 | -76.56 | -84.49 | -85.3 | -84.73 | -86.74 | -75.75 | -71.82 | -65.3 | -53.19 |
| Operating Margin | -3,223.21% | -867.75% | -8,447.51% | -6,187.46% | -6,633.38% | -121,802.82% | -123,491.94% | -3,548.64% | -1,237.98% | -683.74% | -624.78% | -393.92% | -329.75% | -204.55% | -102.96% |
| Earnings before Tax (EBT) 1 | -241.5 | -216.9 | -132.2 | -122.2 | -100.1 | -76.51 | 32.34 | 21.24 | -72.99 | -71.73 | -78.41 | -70.02 | -66.45 | -59.75 | -46.35 |
| Net income 1 | -241.7 | -216.8 | -155.1 | -122.2 | -100.1 | -76.52 | 32.23 | 21.24 | -72.91 | -71.73 | -82.49 | -67.86 | -65.86 | -59.02 | -44.75 |
| Net margin | -3,234.77% | -956.11% | -9,654.55% | -6,280.31% | -6,592.36% | -107,774.65% | 51,987.1% | 892.06% | -1,058.17% | -578.85% | -594.19% | -352.91% | -302.37% | -184.89% | -86.62% |
| EPS 2 | -3.580 | -3.160 | -2.140 | -1.660 | -1.360 | -0.9400 | 0.3800 | 0.2100 | -0.6700 | -0.6600 | -0.6291 | -0.4289 | -0.4211 | -0.3678 | -0.2988 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/9/21 | 11/5/21 | 3/4/22 | 5/9/22 | 8/4/22 | 11/7/22 | 3/29/23 | 5/9/23 | 8/8/23 | 11/7/23 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,232 | 1,106 | 1,151 | 300 | 180 | 241 | 106 | 63.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -469 | -635 | -499 | -650 | - | -327 | -323 | -235 |
| ROE (net income / shareholders' equity) | -31.7% | -49.8% | -46.9% | -94.8% | -93.4% | -105% | -122% | -113% |
| ROA (Net income/ Total Assets) | -26.8% | -39.8% | -35.3% | -69% | - | -40.5% | -80.2% | -88.1% |
| Assets 1 | 2,072 | 1,985 | 1,754 | 1,188 | - | 492.2 | 294.7 | 176.1 |
| Book Value Per Share 2 | 34.40 | 23.20 | 20.40 | 5.260 | 2.370 | 2.040 | 0.7300 | 0.6300 |
| Cash Flow per Share 2 | -7.950 | -10.20 | -7.560 | -9.220 | -4.490 | -1.720 | -1.130 | -0.7400 |
| Capex 1 | 55.7 | 71 | 29 | 14.5 | 8.21 | 6.99 | 6.56 | 6.52 |
| Capex / Sales | 102.12% | 158.99% | 11.56% | 396.04% | 228.19% | 18.68% | 5.23% | 2.53% |
| Announcement Date | 2/21/19 | 2/18/20 | 2/23/21 | 3/4/22 | 3/29/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
0.9228
USD
Average target price
4.062
USD
Spread / Average Target
+340.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.13% | 178M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BLUE Stock
- Financials bluebird bio, Inc.
